A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response.

Abstract

Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

• Authors: T Pearlstein, E Spurell, L A Hohlstein, V Gurney, J Read, C Fuchs, M B Keller
• Journal: Archives of women's mental health (Arch Womens Ment Health) Vol. 6 Issue 2 Pg. 147-51 (Apr 2003) ISSN: 1434-1816 [Print] Austria
• PMID: 12720065 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Serotonin Uptake Inhibitors
• Fluvoxamine

Topics

• Adult
• Body Mass Index
• Bulimia (diagnosis, drug therapy)
• Double-Blind Method
• Female
• Fluvoxamine (therapeutic use)
• Humans
• Male
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Severity of Illness Index